Europäische Union - Rumänisch - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidină - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agenți antineoplazici - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Europäische Union - Rumänisch - EMA (European Medicines Agency)

celgene europe bv - azacitidină - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agenți antineoplazici - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Europäische Union - Rumänisch - EMA (European Medicines Agency)

betapharm arzneimittel gmbh - azacitidină - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agenți antineoplazici - azacitidina betapharm este indicat pentru tratamentul pacienților adulți care nu sunt eligibili pentru transplant de celule stem hematopoietice (tcsh) cu:intermediar-2 și de mare risc sindroame mielodisplazice (smd) potrivit international de prognostic scoring system (ipss),cronică leucemie mielomonocitară (lmmc) cu 10 % la 29% blaști în măduva fără tulburări mieloproliferative,leucemie mieloidă acută (lma) cu 20 % la 30 % blaști și multi-lineage displazie, conform organizației mondiale a sănătății (oms) clasificarea,aml cu > 30 % blaști în măduva în conformitate cu clasificarea oms.

Europäische Union - Rumänisch - EMA (European Medicines Agency)

mylan ireland limited - azacitidină - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agenți antineoplazici - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Europäische Union - Rumänisch - EMA (European Medicines Agency)

accord healthcare s.l.u. - azacitidină - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agenți antineoplazici - azacitidina accord este indicat pentru tratamentul pacienților adulți care nu sunt eligibili pentru transplant de celule stem hematopoietice (tcsh) cu:- intermediar-2 și de mare risc sindroame mielodisplazice (smd) potrivit international de prognostic scoring system (ipss),- cronica leucemia mielomonocitară (lmmc) cu 10-29 % blaști în măduva fără tulburări mieloproliferative,- leucemie mieloidă acută (lma) cu 20-30 % blaști și multi-lineage displazie, potrivit organizației mondiale a sănătății (oms) clasificarea,- aml cu >30% blaști în măduva în conformitate cu clasificarea oms.

Rumänien - Rumänisch - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

seacross pharma (europe) ltd. - irlanda - azacitidinum - pulb. pt. susp. inj. - 25mg/ml - antimetaboliti analogi ai bazelor pirimidinice

Republik Moldau - Rumänisch - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

seacross pharmaceuticals limited - azacitidinum - pulbere pentru suspensie injectabilă - 100 mg

Republik Moldau - Rumänisch - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

accord healthcare s.l.u. - azacitidinum - pulbere pentru suspensie injectabilă - 100 mg

Rumänien - Rumänisch - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

accord healthcare polska sp.z o.o. - polonia - azacitidinum - pulb. pt. susp. inj. - 25mg/ml - antimetaboliti analogi ai bazelor pirimidinice

Rumänien - Rumänisch - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

betapharm arzneimittel gmbh - germania - azacitidinum - pulb. pt. susp. inj. - 25mg/ml - antimetaboliti analogi ai bazelor pirimidinice